Compare ProShares UltraShort Bloomberg Natural Gas ETF (KOLD) vs Summit Therapeutics Inc (SMMT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ProShares UltraShort Bloomberg Natural Gas ETF vs Summit Therapeutics Inc — how do they compare? ProShares UltraShort Bloomberg Natural Gas ETF trades at $28.62, while Summit Therapeutics Inc trades at $15.1 (market cap $12.06B). The key difference: ProShares UltraShort Bloomberg Natural Gas ETF is trading nearer its 52-week high, Summit Therapeutics Inc nearer its low. Which is the better fit depends on your goals.
| KOLD | SMMT | |
|---|---|---|
Sector | Leveraged / Inverse | Health |
52-Week High | $49.39 | $26.98 |
52-Week Low | $13.58 | $12.55 |
Market Cap | — | $12.06B |
Enterprise Value | — | $11.39B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
KOLD, an inverse ETF tracking natural gas futures, trades at $28.34, down 1.05% on the day. Technical indicators show a bullish trend with moving averages supporting upside momentum, while oscillators remain neutral. Recent news highlights natural gas price volatility driven by weather forecasts and LNG export fluctuations, with the ETF positioned as a tactical tool for traders amid market swings.
The outlook for KOLD hinges on continued natural gas price volatility, offering short-term trading opportunities but carrying high risk due to its leveraged structure. Key risks include rapid price reversals in natural gas and macroeconomic shifts affecting energy demand, requiring careful risk management for investors.
Summit Therapeutics (SMMT) trades at $15.23, up 2.42% today, with a bullish technical signal and strong analyst consensus. The stock shows mixed earnings performance but benefits from positive news on ivonescimab's regulatory progress and clinical expansions. Despite negative profitability metrics, investor sentiment is buoyed by a high price target of $38.00 and recent partnership announcements in cancer drug development.
Outlook hinges on FDA approval for ivonescimab by November 2026, offering significant upside if successful. Risks include cash burn, ongoing losses, and fiduciary investigations. The stock presents a high-risk, high-reward opportunity for speculative investors betting on clinical successes.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ProShares UltraShort Bloomberg Natural Gas ETF
KOLD is an inverse leveraged ETF that seeks to provide two times (2x) the inverse daily performance of the Bloomberg Natural Gas Subindex. It is designed for investors looking to profit from falling natural gas prices.
Read more on KOLD →About Summit Therapeutics Inc
Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.
Read more on SMMT →
